Interview by Peter Goodwin with Prof Jakubowiak discusses the RVDD trial, a 4-drug combination of bortezomib, lenalidomide, liposomal doxorubicin, and dexamethasone. Response rates seem impressive and maybe even superior to the RVD regimen, the use of bortezomib with lenalidomide and dexamethasone. Prof Jakubowiak gives his advice for the practicing physician and suggests a longer follow-up is needed to truly establish whether this 4-drug combination is an improvement over existing 3-drug combinations.